HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa, thereby inhibiting thrombus formation and propagation.
| Metabolism | Heparin is partially metabolized by desulfation and depolymerization via reticuloendothelial system (RES) and is also cleared by the kidneys. Exact enzymatic pathways are not fully characterized; hepatic metabolism is minimal. |
| Excretion | Primarily renal (40-60% as unchanged drug); minor biliary/fecal (<10%). |
| Half-life | 30-150 minutes (dose-dependent, nonlinear); at therapeutic doses ~60-90 minutes; prolonged in hepatic/renal impairment. |
| Protein binding | 90-95% (primarily antithrombin III, albumin, fibrinogen). |
| Volume of Distribution | 0.04-0.07 L/kg (confined to plasma). |
| Bioavailability | SC: 20-30% (dose-dependent). |
| Onset of Action | IV: immediate; SC: 20-30 minutes. |
| Duration of Action | IV: 2-4 hours; SC: 8-12 hours (dose-dependent). |
Intravenous: Initial bolus 80 units/kg, then continuous infusion 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment for GFR; monitor anti-Xa levels as heparin is partially renally cleared; accumulation risk in severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No specific Child-Pugh based adjustments; increased bleeding risk in severe hepatic impairment; monitor aPTT closely. |
| Pediatric use | Intravenous: Bolus 75-100 units/kg, infusion 20-25 units/kg/hour; subcutaneous: 250 units/kg every 12 hours. |
| Geriatric use | Reduce initial bolus and infusion rates (e.g., bolus 50 units/kg, infusion 15 units/kg/hour) due to altered pharmacokinetics and increased bleeding risk; monitor aPTT closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Heparin is not excreted into breast milk due to its large molecular size and ionization. It is considered compatible with breastfeeding. M/P ratio is not applicable as heparin is not measurable in milk. |
| Teratogenic Risk | Heparin does not cross the placenta due to high molecular weight and negative charge. Risk of teratogenicity is minimal across all trimesters. Use is considered safe during pregnancy, but caution is advised for bleeding risks at delivery. |
■ FDA Black Box Warning
Heparin is not intended for intramuscular use. Epidural or spinal hematomas may occur in patients anticoagulated with heparin who receive neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis. Risk is increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis (e.g., NSAIDs, antiplatelet agents, other anticoagulants), traumatic or repeated epidural/spinal puncture, or a history of spinal deformity or spinal surgery. Monitor patients for signs and symptoms of neurological impairment.
| Common Effects | fluid replacement |
| Serious Effects |
["Hypersensitivity to heparin or pork products (severe allergic reactions)","History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT)","Active major bleeding (e.g., gastrointestinal, intracranial)","Severe thrombocytopenia (absolute contraindication when related to HIT)","Uncontrolled bleeding disorders (e.g., hemophilia, von Willebrand disease)","Suspected intracranial hemorrhage","Inability to perform adequate coagulation monitoring (e.g., aPTT)"]
| Precautions |
Loading safety data…
| Fetal Monitoring | Monitor platelet count for heparin-induced thrombocytopenia (HIT). Assess for signs of bleeding (e.g., hematuria, bruising). In pregnant women, monitor anti-Xa levels for dose titration (target 0.5-1.0 IU/mL for therapeutic dosing). Fetal monitoring via ultrasound if bleeding complications arise. |
| Fertility Effects | No known adverse effects on fertility from heparin use. It does not interfere with ovulation, implantation, or early embryonic development. |
| ["Hemorrhage: Risk of major bleeding, including intracranial and retroperitoneal bleeding; monitor coagulation tests (aPTT) and adjust dose accordingly","Heparin-induced thrombocytopenia (HIT): Immune-mediated; can cause thrombosis (HITT); monitor platelet counts regularly","Hypersensitivity reactions: Including urticaria, angioedema, anaphylaxis (especially in patients with history of heparin allergy)","Renal impairment: Reduced clearance may require dose adjustment","Elderly: Higher risk of bleeding; use with caution","Neuraxial anesthesia: Risk of spinal/epidural hematoma; monitor neurological status","Heparin resistance: May occur in patients with antithrombin III deficiency or elevated heparin clearance","Hyperkalemia: Heparin can suppress aldosterone synthesis, leading to hyperkalemia; monitor potassium in prolonged use"] |